Augur Signals: News Feed

Report Archive – December 2023

Augur Signals: News Feed
Biotechnology , Healthcare , Alert

Insider Trading Alert: Strategic Moves by Venrock Healthcare Capital Partners III, L.P. in KalVista Pharmaceuticals, Inc.

  • Acquired: Non-Derivative
Insider Trading Alert: Strategic Moves by Venrock Healthcare Capital Partners III, L.P. in KalVista Pharmaceuticals, Inc.
On December 27, 2023, Venrock Healthcare Capital Partners III, L.P. acquired 47,527 shares of KalVista Pharmaceuticals, Inc., enhancing their holdings to 4,092,731 shares. Priced at $12.04 per share, the transaction suggests a bullish trend, supported by a RSI of 92.82 and a Price-to-Book ratio of 2.53. The stock is projected to rise 3-5% in the immediate term, reaching $12.60 to $12.84. This strategic move by Venrock indicates confidence in the company's growth potential.
Biotechnology , Healthcare , Alert

Insider Trading Alert: A Strategic Move by Walter V. Klemp at Moleculin Biotech, Inc.

  • Acquired: Non-Derivative
Insider Trading Alert: A Strategic Move by Walter V. Klemp at Moleculin Biotech, Inc.
On December 26, 2023, Walter V. Klemp from Moleculin Biotech, Inc. purchased 188,374.92 shares at $0.648 each, valued at $122,066.95. Known for his strategic market insights, Klemp's actions often lead to a 27.96% ROI. Despite the sector's volatility, Moleculin Biotech, Inc. shows growth potential with a P/B ratio of 0.75. This insider transaction suggests a bullish outlook, with a predicted price rise of 5-7% in the short term.
Biotechnology , Healthcare , Alert

Insider Buying Alert: BioAtla, Inc. Sees Strategic Acquisition by Lawrence Steinman

  • Acquired: Non-Derivative
Insider Buying Alert: BioAtla, Inc. Sees Strategic Acquisition by Lawrence Steinman
On December 19, 2023, an insider trading alert was triggered for BioAtla, Inc. as Lawrence Steinman, a director, purchased 20,000 shares valued at approximately $39,900. The stock closed at $1.995, with a predicted rise to $2.15 to $2.25 in the short term. Despite mixed valuation metrics, the strategic purchase indicates confidence in BioAtla, Inc.'s potential, suggesting a positive outlook amidst fluctuating biotechnology sector conditions.
Information Technology Services , Technology , Alert

Insider Trading Alert: Nerges Joseph R Buys Common Stock of CSP Inc.

  • Acquired: Non-Derivative
Insider Trading Alert: Nerges Joseph R Buys Common Stock of CSP Inc.
On , an insider trading alert was triggered when Nerges Joseph R, a director of CSP Inc., purchased 6,880.3216 shares valued at $57,047.20. This acquisition reflects his confidence in the company, with a history of 400 transactions and an annualized ROI of 6.58%. The market shows high volatility with a 5-day average volume of 180,400 shares, suggesting potential price movement. The stock price could reach $9.00 to $9.20 in the short term, making CSP Inc. a compelling investment opportunity.
Biotechnology , Healthcare , Alert

Insider Trading Alert: Strategic Moves by Baker Bros. Advisors Lp in IGM Biosciences, Inc.

  • Acquired: Non-Derivative
Insider Trading Alert: Strategic Moves by Baker Bros. Advisors Lp in IGM Biosciences, Inc.
On December 14, 2023, Baker Bros. Advisors Lp, a major insider of IGM Biosciences, Inc., acquired 157,370 shares at $6.50, totaling approximately $1.0M. This transaction signals confidence in the company's prospects despite its high P/B of 5.4 and P/S of 146.11. The insider's historical average return is 23.65%, suggesting a positive short-term outlook. The stock price is expected to rise to $6.60 - $6.70 in the next 5-10 days and potentially reach $6.80 - $7.00 within four weeks.
Software—Application , Technology , Alert

Insider Trading Alert: A Strategic Move by Jafari Amir at Blend Labs, Inc.

  • Acquired: Non-Derivative
Insider Trading Alert: A Strategic Move by Jafari Amir at Blend Labs, Inc.
On December 13, 2023, Jafari Amir of Blend Labs, Inc. purchased 8,547 shares of Class A Common Stock, valued at approximately $16.1k, increasing his total to 68,557 shares. With a history of 38 transactions and an annualized ROI of 41.74%, Amir's actions signal confidence in the company's future, despite its Price-to-Earnings (P/E) ratio of -84.44. Investors remain optimistic, reflected in a Price-to-Sales (P/S) ratio of 8.49. The stock price was $2.1013, with predictions of an increase to $2.15 to $2.25 in the short term.
Biotechnology , Healthcare , Alert

Insider Trading Alert: Baker Bros. Advisors Lp Buys IGM Biosciences, Inc. Stock

  • Acquired: Non-Derivative
Insider Trading Alert: Baker Bros. Advisors Lp Buys IGM Biosciences, Inc. Stock
On December 13, 2023, Baker Bros. Advisors Lp, a major shareholder of IGM Biosciences, Inc., purchased 375,308 shares of common stock, increasing their holdings by 12.45% to 3,390,323 shares, valued at $2.4 million. This transaction occurred in the volatile Biotechnology sector, with IGM Biosciences showing increased trading activity. Despite a negative P/E ratio of -3.09, the high P/B and P/S ratios suggest overvaluation. The purchase may indicate confidence in future prospects, potentially driving short-term price increases. Predictions suggest a 5-8% rise in the next 5-10 days.
Medical Devices , Healthcare , Alert

Insider Trading Alert: Vukovic Vojo Buys Delcath Systems, Inc. Stock

  • Acquired: Non-Derivative
Insider Trading Alert: Vukovic Vojo Buys Delcath Systems, Inc. Stock
On , Vukovic Vojo of Delcath Systems, Inc. bought 40,000 shares, raising his total to 100,000 shares, valued at $125,200. His insider trades show a 20.29% ROI over four weeks. The company, in the Healthcare sector, saw increased trading volume. Despite a negative P/E ratio of -49.58, its high P/B and P/S ratios suggest investor confidence. Short-term price targets range from $3.45 to $3.75, based on historical performance and technical indicators.
Medical Devices , Healthcare

Insider Trading Alert: Strategic Moves by AVITA Medical's Insider

  • Acquired: Non-Derivative
Insider Trading Alert: Strategic Moves by AVITA Medical's Insider
On December 12, 2023, insider trading was noted for AVITA Medical, Inc. (RCEL) on the NCM exchange. David D O'Toole, a director and ten percent owner, purchased 950 shares at $12.27 each, totaling $11,656.50. Known for strategic investments with a 14.58% ROI over four weeks, O'Toole's recent activity could signal confidence in the company's future. Despite this, AVITA Medical, Inc. appears overvalued on a Price-to-Book (P/B) ratio basis, rated 10 out of 10. Investors should consider both insider confidence and valuation metrics when evaluating potential investments.
Telecom Services , Communication Services , Alert

Insider Trading Alert: Ribbon Communications Inc. Sees Strategic Purchase by Lopez Miguel A

  • Acquired: Non-Derivative
Insider Trading Alert: Ribbon Communications Inc. Sees Strategic Purchase by Lopez Miguel A
Lopez Miguel A, an officer at Ribbon Communications Inc., purchased 2,000 shares of Common Stock at $2.18 per share, totaling $4,360. This transaction increased his holdings to 244,165 shares. With a Price-to-Earnings (P/E) ratio of 13.22 and a Price-to-Book (P/B) ratio of 1.7, the company shows modest undervaluation. The Relative Strength Index (RSI) indicates nearing overbought conditions, while MACD suggests bullish momentum. The price is expected to rise to $2.25 to $2.35 in the short term.

Back

Pages total: 3

Calendar